ANAB
NASDAQ
$50.29
AnaptysBio Inc (ANAB)
AnaptysBio, Inc., a clinical-stage biotechnology company, is dedicated to developing therapeutic product candidates for inflammation and immuno-oncology indications. The company is headquartered in San Diego, California.
Sector:
Healthcare
Industry:
Biotechnology
Strong Buy
Target: $87.09 (+73.18%)
Market Cap
$1.62B
Revenue 5Y CAGR
+26.67%
Free Cash Flow Yield
0.27%
Beta (5Y)
0.80
Price Chart
Valuation
Market Cap$1.62B
P/S6.90
P/B129.66
Profitability
Total Revenue (TTM)$232M
Gross Profit (TTM)$104M
EBITDA$41M
Profit Margin-11.5%
Operating Margin-135.5%
EPS-$0.88
Financial Health
Free Cash Flow Yield0.27%
Growth & Risk
EPS 5Y CAGR-4.15%
Revenue 5Y CAGR+26.67%
Beta (5Y)0.80
Sharpe Ratio1.73